Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | £25,872 | £21,828 | £35,817 | £45,020 |
| - Cash | £854 | £1,136 | £1,169 | £675 |
| + Debt | £6,025 | £10,612 | £12,371 | £7,631 |
| Enterprise Value | £31,043 | £31,304 | £47,019 | £51,976 |
| Revenue | £44,392 | £39,267 | £34,669 | £29,494 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Gross Profit | £19,634 | £17,102 | £15,814 | £13,924 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| EBITDA | £10,640 | £9,371 | £8,247 | £7,387 |
| % Margin | 24% | 23.9% | 23.8% | 25% |
| Net Income | £5,830 | £4,614 | £5,123 | £5,128 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| Operating Cash Flow | £8,364 | £6,085 | £5,493 | £6,023 |
| Capital Expenditures | -£2,235 | -£2,710 | -£2,939 | -£2,558 |
| Free Cash Flow | £6,130 | £3,375 | £2,554 | £3,465 |